An observational study in Abruptio Placentae; Affecting Fetus or Newborn, sponsored by Hatice Akkaya. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-29.
Sponsored by Hatice Akkaya · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. Most abruptions accept to be related to a chronic placental disease process. Therefore, it is very important to understand these processes. To analyze maternal and neonatal effects of placental abruption(PA) through a novel classification in the presence of hypertension. Initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.
Objective: We aimed to classify placental abruption according to hypertension status.
Methods: This retrospective cohort designed study was conducted on 115 pregnant women with placental abruption. The main parameters scanned and recorded from the hospital database and patient medical files. Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive). Maternal demographical and clinical characteristics (abdominal pain, vaginal bleeding) were recorded. APGAR scores below 5 at 1 and 5 min., fetal or neonatal death, admission and length of stay in Neonatal Intensive Care Unit(NICU) were also investigated and compared between the groups.
23 studies on the registry are indexed under Abruptio Placentae; 4 are open to participants now.
This study's enrollment of 115 is below the median of 184 across 12 observational studies indexed under Abruptio Placentae.
Browse Abruptio Placentae studies →Hatice Akkaya is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Two groups were formed according to presence or absence of hypertension (53 hypertensive, 62 normotensive) who has placental abruption.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
Other: clinical assesment
Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).
Other: clinical assesment
Comparison of Hypertensive group and normotensive group
blood pressure measurement
mm Hg
Time frame: 2 minute
hemogram parameters WBC(white blood cell) ,PLT(Platelet), MPV(mean platelet volume), HGB(hemoglobin), Neutrophil lymphocyte ratio..)
complete blood test retrospective complete blood count analysis
Time frame: first 1 hour
maternal and newborn length, weight
centimeters,kilogram
Time frame: 5 minute
APGAR score
1st and 5th minute newborn assesment
Time frame: 5 minute
No study locations are listed for this record.
Plan to share: No — The data belonging to participant only will be available to any researcher or editorial review board if needed.
No publications or documents are linked to this record.
Ran from Jan 2016 to primary completion in Apr 2017, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hatice Akkaya